Joint Program for Clinical Research and
Clinical Trial Management offered through the PAREXEL Academy
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services provider, and Kyoto
Pharmaceutical University (KPU), a private pharmacy and science
university, today announced the new Joint Program for Clinical
Research and Clinical Trial Management. The academic program offers
undergraduate students an accredited, seven-week course designed to
prepare them for careers in the biopharmaceutical industry.
The collaboration is intended to meet the needs of a growing
number of Japanese biopharmaceutical companies conducting clinical
research inside and outside of Japan as part of global drug
development initiatives. The course combines PAREXEL®’s extensive
regulatory and clinical research expertise with Kyoto
Pharmaceutical University’s extensive experience developing
highly-specialized research abilities in their
“pharmacist-scientists” students. All classes will be conducted in
English by non-Japanese lecturers from the PAREXEL Academy and are
consistent with global clinical trial standards and practices. The
first session begins in KPU’s fiscal year 2016 and will be offered
annually.
“In Japan, clinical trial management is not widely taught in an
academic setting. In partnership with Kyoto Pharmaceutical
University, we are offering a unique educational program that
provides a functional foundation in clinical research and clinical
trial management. We believe this program is an innovative way to
accelerate the penetration of global standards of clinical research
in Japan while also helping to address the current clinical
research workforce shortage in the country,” said Shogo Nakamori,
Corporate Vice President, Asia-Pacific and General Manager, PAREXEL
Japan.
Ken-ichi Inui, President, Kyoto Pharmaceutical University,
commented that “Kyoto Pharmaceutical University provides an
integrated education over a six-year period, with the purpose of
training pharmacists with advanced specialized skills and research
capabilities, that is, ‘pharmacist-scientists’. In addition, with
an interest towards globalization in 2012, we decided to use
English instead of Japanese for graduation-thesis presentations by
six-year students. Through our partnership with the PAREXEL
Academy, KPU’s Joint Program for Clinical Research and Clinical
Trial Management will benefit students interested in working in the
pharmaceutical industry, hospitals and regulatory affairs.”
PAREXEL established operations in Japan in 1995 and has more
than 1,000 employees based in Tokyo, Kobe and Osaka. The Company
provides clinical research services, consulting and technology
offerings to drug developers. In addition, for more than a decade,
the PAREXEL Academy has designed and implemented a wide range of
learning programs tailored to enable clinical research management
practices for learners inside and outside of PAREXEL in Asia,
Europe, and the United States. Since inception, approximately 1,000
students have graduated from the Academy’s programs.
About Kyoto Pharmaceutical University
Kyoto Pharmaceutical University (KPU) was founded as a
pre-pharmacy course in Kyoto Private German School in 1884 and is
the second oldest private school of pharmacy in Japan. Over 22,000
graduates of KPU have contributed greatly, with high appraisal, in
pharmaceutical companies, hospitals, pharmacies, academia, and
administrative agencies. The new six-year system in undergraduate
pharmacy education of Japan started in 2006. KPU puts special
emphasis on postgraduate education as well as undergraduate
education. A four-year doctorate course which follows upon the
six-year undergraduate course is important for the training of
future leaders (pharmacists with PhD) in various areas related with
pharmaceutical sciences. In 2012, KPU established a four-year
doctorate course, consisting of “basic pharmacy course,” “clinical
pharmacy course,” ”cancer research course,” specializing in cancer
study in cooperation with some medical schools, and “regulatory
science course” linked with the Pharmaceutical and Medical Devices
Agency, Japan.
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services organization, providing a broad range of
expertise-based contract research, consulting, medical
communications, and technology solutions and services to the
worldwide pharmaceutical, biotechnology and medical device
industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, medical
education and reimbursement. PAREXEL Informatics provides advanced
technology solutions, including medical imaging, to facilitate the
clinical development process. Headquartered near Boston,
Massachusetts, PAREXEL has offices in 80 locations in 51 countries
around the world, and had approximately 18,620 employees in the
first quarter. For more information about PAREXEL International
visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its
affiliates.
This release contains “forward-looking” statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements contained herein
that are not statements of historical fact may be deemed
forward-looking statements. Without limiting the foregoing, the
words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. The
Company’s actual future results may differ materially from the
results discussed in the forward-looking statements contained in
this release. Important factors that might cause such a difference
include, but are not limited to, risks associated with: actual
operating performance; actual expense savings and other operating
improvements resulting from restructurings, including expense
savings from the $30 – $45 million restructuring charge disclosed
in the press release dated June 23, 2015; the loss, modification,
or delay of contracts which would, among other things, adversely
impact the Company’s recognition of revenue included in backlog;
the Company’s dependence on certain industries and clients; the
Company’s ability to win new business, manage growth and costs, and
attract and retain employees; the Company’s ability to complete
additional acquisitions, and to integrate newly acquired businesses
including the acquisition Quantum Solutions India, or enter into
new lines of business; the impact on the Company’s business of
government regulation of the drug, medical device and biotechnology
industry; consolidation within the pharmaceutical industry and
competition within the biopharmaceutical services industry; the
potential for significant liability to clients and third parties;
the potential adverse impact of health care reform; and the effects
of foreign currency exchange rate fluctuations and other
international economic, political, and other risks. Such factors
and others are discussed more fully in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151112005042/en/
PAREXEL InternationalCristi Barnett, +1
781-434-4019Cristi.Barnett@PAREXEL.comorPAREXEL International
JapanSatoko Okubo, +81-(0)3-3537-5090Satoko.Okubo@PAREXEL.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Apr 2023 to Apr 2024